Author

Fabio Cataldi 1

1 PFIZER INC

CORRELATION OF BIOMARKERS OF INFLAMMATION WITH CLINICAL AND ENDOSCOPIC ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: DATA FROM CELEST

Jean-Frederic Colombel, Laurent Peyrin-Biroulet, Silvio Danese, Simon Travis, Gerald Dryden, Robert Hardi, Michael S Epstein, Wen Zhou, Fabio Cataldi, Bidan Huang, Ana Paula Lacerda, Julian Panés

DETERMINATION OF IMMUNE SURVEILLANCE IN CEREBROSPINAL FLUID (CSF) IN PATIENTS WITH CROHN’S DISEASE: INITIAL RESULTS OF THE TOSCA STUDY

André Van Gossum, Richard Ransohoff, Olaf Stuve, John Cheng, Yanhua Zhang, Sunday Rivers, Gail M. Comer, Bo Jin, Kenneth Gorelick, Mina Hassan-Zahraee, Fabio Cataldi, Walter Reinisch, Geert R. D'Haens

EFFECT OF ETRASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Silvio Danese, Kiyomi Komori, Rathi D. Ryan, Fabio Cataldi, Caroline A. Lee, Martina Goetsch, Britta Siegmund

EFFICACY AND SAFETY OF OLORINAB, A PERIPHERALLY ACTING, HIGHLY SELECTIVE, FULL AGONIST OF CANNABINOID RECEPTOR 2, FOR THE TREATMENT OF ABDOMINAL PAIN IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: RESULTS FROM A PHASE 2B RANDOMIZED STUDY

Brooks D Cash, Anthony J. Lembo, David C. Kunkel, Brett A. English, Beatriz Lindstrom, Sharon Skare, Charlie Liu, Stewart Turner, Fabio Cataldi, Saleem Desai, Donald Lipkis, Jan Tack, Lin Chang

Efficacy and safety of upadacitinib as an induction therapy for patients with moderately-to-severely active ulcerative colitis: combined results from 382 subjects in the phase 2b study U-ACHIEVE

Peter D.R. Higgins, Xavier Hebuterne, Jesse Siffledeen, Wen Zhou, Fabio Cataldi, Wangang Xie, Ana P. Lacerda, Silvio Danese

EFFICACY OF UPADACITINIB AS AN INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS, WITH OR WITHOUT PREVIOUS TREATMENT FAILURE OF BIOLOGIC THERAPY: DATA FROM THE DOSE-RANGING PHASE 2B STUDY U-ACHIEVE

Remo Panaccione, Geert R. D'Haens, William Sandborn, Subrata Ghosh, Stefan Schreiber, Satoshi Tanida, Wen Zhou, Fabio Cataldi, David Pugatch, Bidan Huang, Wangang Xie, Peter Higgins

Efficacy of upadacitinib as an induction therapy in severe and refractory ulcerative colitis: sub-group analysis of the phase 2b study U-ACHIEVE

Geert R. D'Haens, James Lindsay, Edward Loftus, Wen Zhou, Fabio Cataldi, Wangang Xie, David Pugatch, Remo Panaccione

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Brian G. Feagan, Laurent Peyrin-Biroulet, William J. Sandborn, Geert R. D'Haens, Julian Panés, Andres Yarur, Douglas C. Wolf, Timothy Ritter, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J. Rabbat, Michael Chiorean, Filip Baert, Bruce E. Sands, Marla C. Dubinsky, Severine Vermeire, Martina Goets

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

William J. Sandborn, Severine Vermeire, Laurent Peyrin-Biroulet, Marla C. Dubinsky, Julian Panés, Andres Yarur, Timothy Ritter, Filip Baert, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J. Rabbat, Michael Chiorean, Douglas C. Wolf, Bruce E. Sands, Geert R. D'Haens, Silvio Danese, Martina Goetsch

Identification of biomarkers and mechanistic insight for upadacitinib in Crohn's disease: Serum inflammatory mediator analysis from the Phase 2b CELEST study

Severine Vermeire, Heath M. Guay, Bram Verstockt, Feng Hong, Wan-Ju Lee, Fabio Cataldi, Ana P. Lacerda, Silvio Danese

Item 1 - 10 / 19
1
2